

Ludovico Arcuri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2897529/publications.pdf>

Version: 2024-02-01

8
papers

348
citations

1307594

7
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

697
citing authors

#	ARTICLE	IF	CITATIONS
1	LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 49.	2.9	82
2	Age-dependent dopamine transporter dysfunction and Serine129 phospho- α -synuclein overload in G2019S LRRK2 mice. <i>Acta Neuropathologica Communications</i> , 2017, 5, 22.	5.2	73
3	G2019S LRRK2 mutation facilitates α -synuclein neuropathology in aged mice. <i>Neurobiology of Disease</i> , 2018, 120, 21-33.	4.4	56
4	Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity. <i>Movement Disorders</i> , 2015, 30, 1728-1738.	3.9	50
5	Differential regulation of striatal motor behavior and related cellular responses by dopamine D2L and D2S isoforms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 198-203.	7.1	41
6	Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. <i>Neurobiology of Disease</i> , 2016, 89, 55-64.	4.4	24
7	Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists. <i>British Journal of Pharmacology</i> , 2018, 175, 782-796.	5.4	16
8	Parkinson's disease: no NOP, new hope. <i>Oncotarget</i> , 2017, 8, 8995-8996.	1.8	6